Protocol to investigate the effect of cyclo-oxygenase (COX)-2 inhibition on reducing central sensitisation of pain in osteoarthritis
ISRCTN | ISRCTN36231538 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN36231538 |
EudraCT/CTIS number | 2006-000395-32 |
Secondary identifying numbers | N/A |
- Submission date
- 28/07/2008
- Registration date
- 30/09/2008
- Last edited
- 17/04/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Ernest Choy
Scientific
Scientific
Weston Education Centre
10 Cutcombe Road
London
SE5 9RJ
United Kingdom
Phone | +44 (0)207 848 5206 |
---|---|
kch-tr.kms-ctu@nhs.net |
Study information
Study design | Non-randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Non randomised controlled trial |
Study setting(s) | Not specified |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | Protocol to investigate the effect of cyclo-oxygenase (COX)-2 inhibition on reducing central sensitisation of pain in osteoarthritis |
Study objectives | This study aims to assess whether cyclo-oxygenase (COX)-2 selective inhibition by etoricoxib reduces central sensitisation of pain in patients with chronic osteoarthritis (OA) using functional magnetic resonance imaging (fMRI) scan. |
Ethics approval(s) | St Thomas' Hospital Research Ethics Committee. Date of approval: 23/03/2006 |
Health condition(s) or problem(s) studied | Osteoarthritis |
Intervention | 16 patients will be recruited from the Rheumatology Outpatient Clinic of King's College Hospital. 16 healthy controls will be recruited from the staff and student population at King's College London (32 participants in total). Interventions: Etoricoxib (oral) 60 mg daily for 2 weeks vs no treatment |
Intervention type | Other |
Primary outcome measure | 1. Pressure pain thresholds (PPTs) will be determined using a pressure algometer. Patients will be asked to indicate the site of ongoing pain on a mannequin. This site and the homologous contralateral site will be marked with a pen and noted in the patient record. The pressure pain level will be assessed twice at each site (rate of stimulus increase 50 kPa; probe area 1 cm2) and the average of two perception levels will be calculated as the individual PPT for that site. 2. Functional MRI (fMRI) will be used to assess brain responses to a standardised pain provocation produced by pressure delivered to a non fibromyalgia syndrome (FMS) pressure point of the knee. The fMRI evaluation will involve multiple 8 min scans using an event-related design. Pressure stimuli of 2.5 seconds duration will be delivered to the right knee at random intervals varying between 10 and 20 seconds. This will then be repeated for the left knee. The control group will have only one scan. Assessments will be carried out at baseline and after 2 weeks of treatment with etoricoxib for OA patients. Healthy controls will only complete baseline assessments. |
Secondary outcome measures | 1. Mechanoreceptive function 2. Sensitivity to stimulus invoked pain Assessments will be carried out at baseline and after 2 weeks of treatment with etoricoxib for OA patients. Healthy controls will only complete baseline assessments. |
Overall study start date | 01/09/2008 |
Completion date | 01/03/2009 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | 32 |
Key inclusion criteria | For all participants: 1. Both males and females, age >18 years old 2. Those who are right handed 3. Signed informed consent For participants with OA: 1. Patients with ACR criteria defined OA of the knee 2. Radiological OA 3. Patients who have been suffering from pain for more than 1 year |
Key exclusion criteria | 1. History of hypersensitivity to the active substance or to any of the excipients 2. Active peptic ulceration or active gastro-intestinal (GI) bleeding 3. Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions after taking acetylsalicylic acid or non-steroidal anti-inflammatory drugs (NSAIDs) including COX-2 inhibitors 4. Pregnancy and lactation 5. Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score >=10) 6. Estimated renal creatinine clearance <30 ml/min 7. Inflammatory bowel disease 8. Congestive heart failure (New York Heart Association [NYHA] II-IV) 9. Patients with hypertension whose blood pressure has not been adequately controlled |
Date of first enrolment | 01/09/2008 |
Date of final enrolment | 01/03/2009 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Weston Education Centre
London
SE5 9RJ
United Kingdom
SE5 9RJ
United Kingdom
Sponsor information
Kings College London (UK)
University/education
University/education
Strand
London
WC2R 2LS
England
United Kingdom
Phone | +44 (0)20 7836 5454 |
---|---|
kch-tr.kms-ctu@nhs.net | |
Website | http://www.kcl.ac.uk |
https://ror.org/0220mzb33 |
Funders
Funder type
Industry
Merck Sharp & Dohme Ltd (MSD) (UK)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Basic results | No | No |
Editorial Notes
17/04/2019: A EudraCT link has been added to the basic results (scientific)
26/08/2016: No publications found, verifying study status with principal investigator